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Introduction 
Langerhans Cell Histiocytosis (LCH) is a 
rare disease characterized by aberrant 
proliferation of a specific dendritic 
(Langerhans) cell belonging to the monocyte 
macrophage system.1 These cells can 
infiltrate virtually any organ without 
inducing dysfunction.2  LCH is encountered 
more often in children, with a peak age range 
of 1-3 years and an incidence of 3-5 cases per 
million per year and a male to female ratio of 
2:1.3  LCH is rare in adults and the incidence 
may be underestimated due to the fact that 
many cases likely go undiagnosed. 
In order of decreasing frequency, the 
presenting symptoms are skin rash, dyspnea 
or tachypnea, polyuria and polydipsia, bone 
pain, lymphadenopathy, weight loss, fever, 
gingival hypertrophy, ataxia, and memory 
problems.4  Regarding the endocrine system, 
LCH has a particular predilection for 
involvement of the hypothalamo–pituitary 
axis (HPA), leading to diabetes insipidus 
(DI) in up to 50% of cases. In a recent 
analysis, DI was the most common and 
permanent consequence of LCH, occurring in 
24% of patients.5 Other endocrine 
deficiencies can develop in up to 20% of 
patients.5,6  Endocrine manifestations include 
DI followed by growth hormone deficiency 
with a median latency of about one year, 
followed by gonadotropin deficiency  with  a  
median latency of about seven years from the  
 
 
 
diagnosis of DI. ACTH and TSH deficiency 
also have been described.7 
The length of time from the first 
symptom(s) to diagnosis is frustratingly long. 
Many patients wait one to four years before 
the correct diagnosis is made, and others 
have symptoms for 5 to 20 years.8 The 
difficulty in making an accurate diagnosis is 
reflected in the long time from symptom 
onset to diagnosis, lack of clinical suspicion, 
and the variable characteristics of the disease. 
Diagnosis is based on electron microscopy or 
immunohistochemistry (positivity for S100 
protein and CD1a).9-11  Treatment is based on 
the extent of the disease and the site of 
involvement.12  
We report a case of a woman who had 
symptoms of diabetes insipidus for many 
years before she presented with headache and 
subsequently was diagnosed with LCH. 
 
Case Report 
A 53-year-old post-menopausal female 
presented to her primary care physician with 
complaints of headache and blurry vision for 
two to three months.  An MRI of the brain 
revealed an enhancing lesion in the 
suprasellar hypothalamic area extending into 
the brain stem measuring 2.8 cm (AP) x 2.4 
cm (transverse) x 1.6 cm with hyperintensity 
on FLAIR (see Figure 1).  During this time 
frame, the patient also was diagnosed with 
hypothyroidism. In retrospect, the patient had 
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polyuria, compensated with polydipsia, for a 
few years preceding the headache.  An MRI-
guided right fronto-temporal craniotomy was 
completed with guided biopsy.  
 
 
Figure 1.  MRI of the brain showing the 
lobulated enhancing mass centered in the 
suprasellar location.  
 
Pre-biopsy biochemical evaluation 
revealed normal sodium (140 mmol/L). Post-
operatively, while in recovery room, the 
patient had greater than 800 ml of urine 
output over the course of three hours.  Over 
the next two hours, she became lethargic, 
developed respiratory acidosis, and was 
intubated for respiratory failure.  She had 
urine output of about nine liters over a period 
of 12 hours.  Her blood chemistry 12 hours 
post-biopsy revealed hypernatremia with 
serum sodium of 166 mmol/L. An endo-
crinologist was consulted to manage diabetes 
insipidus. 
The patient initially was treated with 
DDVAP 1 mcg subcutaneously every eight 
hours with resultant improvement in 
polyuria.  Fluids were replaced first with a 
combination of quarter-normal saline and 
half-normal saline with the addition of free 
water via naso-gastric feeding tube and later 
replaced with half-strength saline only.  With 
these measures, her sodium improved to 146 
mmol/L over a span of 48 hours. At this 
point, she was extubated. Serum sodium was 
maintained in normal range with oral 
maintenance fluids and DDAVP 0.2 mg by 
mouth twice daily.  Perioperatively while she 
was intubated, she received dexamethasone, 
and IV levothyroxine 50 mcg daily.  
The pathology report revealed gliosis 
with scattered atypical cells, patchy chronic 
inflammation, and Rosenthal fibers.  
Histiocytic infiltrate was present consistent 
with Langerhans cell histiocytosis.  A patchy 
polymorphous inflammatory infiltrate 
consists of small lymphocytes, plasma cells, 
eosinophils, sometimes multiple per high 
power field, and larger histiocytes with 
clefted "C" to horseshoe-shaped nuclei 
(immunoreactive with CD1a). A few 
multinucleated cells including one Touton-
type giant cell was noted, but no well-formed 
granulomas were found.  No emperipolesis 
was noted.  No necrosis was detected.  CD1a 
stains were positive for multiple of the cells 
with abundant cytoplasm and C-shaped 
nuclei. S100 highlighted frequent 
immunoreactive cells, inclusive of, yet more 
than, the CD1a population of cells (see 
Figure 2).  CD20 highlighted multiple small 
lymphocytes (see Figure 3).  No CD117 
immunoreactive cells were identified ruling 
out CNS germinoma. CNS lymphoma was 
ruled out with appropriate stains. The 
consulting oncologist recommended 
chemotherapy as an outpatient.  
Additional workup during hospital stay 
revealed panhypopituitarism.  Dexametha-
sone was discontinued post-extubation and 
the 8 am cortisol level, more than 48 hours 
later, was 1.0 mcg/dl indicating adrenal 
insufficiency.  FSH and LH were low at 0.7 
µU/mL and 0.2 µU/mL respectively, which 
in a post-menopausal female was suggestive 
of pituitary dysfunction. TSH was 0.07 
µU/mL and free T4 was 1.0 ng/dL presenting 
a picture of central hypothyroidism. The dose 
of levothyroxine was changed from 50 mcg 
intravenously daily to her home dose of 112 
mcg daily by mouth. Physiological 
hydrocortisone replacement was started at 20 
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mg in the morning and 10 mg in the evening.   
DI was treated with a maintenance dose of 
DDVAP 0.2 mg by mouth twice daily. 
Eventually she underwent rehabilitation and 
was discharged home. 
After discharge,  the  patient  was  treated  
with chemotherapy.  Following treatment, 
she had about 33% shrinkage of the tumor 
size on MRI.  Her visual symptoms have 
resolved but she continued to have pan-
hypopituitarism and was on adequate 
pituitary hormone supplements. 
 
 
 
Figure 2.  Numerous Langerhans cells were 
confirmed immunohistochemically (anti-
CD1a, original magnification x200).
 
 
 
Figure 3.  A biopsy from the suprasellar mass 
contained patchy areas of a cellular 
lymphohistiocytic infiltrate, including 
scattered Langerhans cells with typical C-
shaped nuclei.  
 
Discussion 
LCH is a rare disorder characterized by 
idiopathic proliferation of specialized bone 
marrow derived Langerhans cells.  LCH may 
be systemic or localized and its clinical 
manifestations are variable.  In adults, 
infiltration is seen most frequently in bones 
(52%), lungs (40%), and skin (7%); whereas 
involvement of liver, spleen, lymph nodes 
and bone marrow is less frequent.4,13,14   In 
view of the non-specific symptoms, LCH 
usually is misdiagnosed or under diagnosed. 
This case was unique as her symptoms of 
LCH were related only to pituitary 
involvement. The patient had symptoms of 
DI for a few years, but the diagnosis was 
delayed until the patient had symptoms from 
the pituitary mass including headache and 
visual complains.  By then, the patient had 
lost anterior and posterior pituitary hormone 
functions including antidiuretic hormone, 
thyroid, gonadotropic hormones, and cortico- 
 
trophin hormones.  The long mean time from 
symptom onset to diagnosis was due, in part, 
to lack of clinical suspicion related to the low 
incidence of the disease.  
Diagnosis of LCH is based on electron 
microscopy or immunohistochemistry (posi-
tivity for S100 protein and CD1a). Treatment 
is based on the extent and site of disease 
involvement. Options include conservative 
therapy with topical steroids, hormone 
replacement therapy, or local excision versus 
aggressive therapy including radiation, 
chemotherapy, anti-CD1a mono-clonal 
antibodies and/or organ or stem cell 
transplantation.15-17  
This report attempted to identify 
evolution of pituitary dysfunctions, 
histopathological picture, and progress of the 
disease. Health care professionals should be 
aware of LCH as a possible cause of DI. An 
increased awareness could lead to early 
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diagnosis and treatment before more 
permanent damage occurs.  The quality of 
life may be impaired by long-term sequelae 
including orthopedic problems, deafness, 
pituitary insufficiency, neurological defects, 
and impaired liver function. Most reported 
cases have systemic involvement.8,15  
Patients that initially present with DI have 
had subsequent abnormalities of other 
pituitary hormones that might take a few 
years to manifest. Thus, an increased 
suspicion and evaluation of other anterior 
pituitary hormone dysfunction on initial 
evaluation and follow-up are needed.
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